Penn Spinout Vittoria Biotherapeutics Emerges from Stealth Mode with $10M Seed Round

Jun 07, 2022

A Philadelphia life sciences company spun out of a University of Pennsylvania research lab is emerging from stealth mode with nearly $10 million from a seed funding round.

Vittoria Biotherapeutics’ mission is to overcome current limitations of chimeric antigen receptor (CAR) T-cell therapeutics by using its unique cell engineering and gene editing technologies to create new therapies that address unmet clinical needs.┬áThe technology the company is attempting to commercialize was developed by Dr. Marco Ruella, a hematologist from Italy who came to the United States 10 years ago to study under Penn CAR T-cell pioneers Dr. Carl June and Saar Gill.

Read more >